CMC Regulatory Considerations for Antibody-Drug Conjugates

Area of Science:

• Biopharmaceutical Manufacturing
• Drug Development
• Chemical Biology

Background:

• Antibody-drug conjugates (ADCs) combine antibodies with potent drugs for targeted therapy.
• ADC manufacturing involves intricate processes for antibody, drug, and linker production, followed by conjugation.
• This complexity necessitates robust control strategies and analytical characterization.

Purpose of the Study:

• To outline an integrated quality approach for ADC development.
• To provide guidance on structuring Module 3 of the Common Technical Document for ADCs.
• To address regulatory expectations for ADC process control and characterization.

Main Methods:

• Application of scientific understanding of ADC production processes.
• Implementation of risk-based approaches to quality management.
• Analysis of regulatory documentation requirements for ADCs.

Main Results:

• A risk-based strategy can demonstrate quality at critical control points.
• This approach minimizes redundant comparability studies and product characterization.
• Streamlined process qualification focusing on critical quality attributes is enabled.

Conclusions:

• Integrated quality management is essential for complex ADC manufacturing.
• Flexible structuring of regulatory documents is feasible with adequate cross-referencing.
• A risk-based approach facilitates efficient and compliant ADC development throughout the product lifecycle.